Q2 FY2026 EarningsQ2 FY26 results missed consensus estimates on the bottom line: GAAP Net Loss of $12.75M vs. $10.51M expected, and EPS of -$0.41 vs. -$0.265 mean estimate. Operating loss of $14.49M was wider than the $11.71M consensus, driven by persistent G&A expenses and direct R&D costs for Senti-202 totaling $4.88M. Liquidity remains critical with only $6.46M in cash and a 'going concern' warning, prompting a strategic pivot via a definitive merger agreement to divest clinical assets in exchange for Contingent Value Rights (CVRs).
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Senti Biosciences(SNTI) the Revenue is 17 K (--%), Beat estimate;the EBIT is -14.49 M (+13.75%), Miss estimate;the EPS is -0.41 (+26.79%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.00B--
0.00B--
+0.00B--%
EBITMiss expectations
-0.01B13.75%
-0.01B30.30%
-0.00B16.55%
EPSMiss expectations
-0.4126.79%
-0.26552.68%
-0.145025.89%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf